A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia (vol 111, pg 3327, 2020)

被引：0
|
作者：
Sekiguchi, Naohiro
Rai, Shinya
Munakata, Wataru
Suzuki, Kenshi
Handa, Hiroshi
Shibayama, Hirohiko
Endo, Tomoyuki
Terui, Yasuhito
Iwaki, Noriko
Fukuhara, Noriko
Tatetsu, Hiro
Iida, Shinsuke
Ishikawa, Takayuki
Shiibashi, Ryota
Izutsu, Koji
机构：
来源：
CANCER SCIENCE | 2021年 / 112卷 / 04期
关键词：
D O I：
10.1111/cas.14818
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1669 / 1669
页数：1
相关论文
共 50 条
  • [21] A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
    Arellano, Martha L.
    Borthakur, Gautam
    Berger, Mark
    Luer, Jill
    Raza, Azra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (06): : 534 - 539
  • [22] Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma
    Abou-Alfa, Ghassan K.
    Mayer, Robert
    Venook, Alan P.
    O'Neill, Allison F.
    Beg, Muhammad S.
    LaQuaglia, Michael
    Kingham, Peter T.
    Kobos, Rachel
    Basturk, Olca
    Brennan, Cameron
    Yopp, Adam
    Harding, James J.
    Leong, Stephen
    Crown, John
    Hoti, Emir
    Leonard, Gregory
    Ly, Michele
    Bradley, Mikaela
    Valentino, Emily
    Markowitz, David
    Zukiwski, Alexander
    Ren, Ken
    Gordan, John D.
    ONCOLOGIST, 2020, 25 (12): : E1837 - E1845
  • [23] Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
    Sherman, E.
    Lee, J. L.
    Debruyne, P. R.
    Keam, B.
    Shin, S. J.
    Gramza, A.
    Caro, I.
    Amin, R.
    Shah, K.
    Yan, Y.
    Huddart, R.
    Powles, T.
    ESMO OPEN, 2023, 8 (02)
  • [24] Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study (vol 7, pg e112, 2020)
    Owen, R. G.
    McCarthy, H.
    Rule, S.
    LANCET HAEMATOLOGY, 2021, 8 (04): : E249 - E249
  • [25] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (vol 105, pg 309, 2017)
    Komatsu, Norio
    Kirito, Keita
    Shimoda, Kazuya
    Ishikawa, Takayuki
    Ohishi, Kohshi
    Ohyashiki, Kazuma
    Takahashi, Naoto
    Okada, Hikaru
    Amagasaki, Taro
    Yonezu, Toshio
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 387 - 387
  • [26] Single-agent Ibrutinib is efficacious and well tolerated in Rituximab-refractory patients with Waldenstrom's Macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (INNOVATE™)
    Buske, C.
    Trotman, J.
    Tedeschi, A.
    Matous, J., V
    Macdonald, D.
    Tam, C.
    Toumilhac, O.
    Ma, S.
    Oriol, A.
    Heffner, L. T.
    Shustik, C.
    Garcia-Sanz, R.
    Cornell, R. F.
    Fernandez de Larrea, C.
    Castillo, J. J.
    Granell, M.
    Kyrtsonis, M-C
    Leblond, V
    Symeonidis, A.
    Singh, P.
    Li, J.
    Graef, T.
    Bilotti, E.
    Treon, S.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 119 - 119
  • [27] Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma
    Foran, JM
    Rohatiner, AZS
    Coiffier, B
    Barbui, T
    Johnson, SA
    Hiddemann, W
    Radford, JA
    Norton, AJ
    Tollerfield, SM
    Wilson, MP
    Lister, TA
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 546 - 553
  • [28] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
    Gopal, Ajay K.
    Schuster, Stephen J.
    Fowler, Nathan H.
    Trotman, Judith
    Hess, Georg
    Hou, Jing-Zhou
    Yacoub, Abdulraheem
    Lill, Michael
    Martin, Peter
    Vitolo, Umberto
    Spencer, Andrew
    Radford, John
    Jurczak, Wojciech
    Morton, James
    Caballero, Dolores
    Deshpande, Sanjay
    Gartenberg, Gary J.
    Wang, Shean-Sheng
    Damle, Rajendra N.
    Schaffer, Michael
    Balasubramanian, Sriram
    Vermeulen, Jessica
    Cheson, Bruce D.
    Salles, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2405 - +
  • [29] Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
    Thomas, Sheeba K.
    Harb, Wael A.
    Beck, Joseph Thaddeus
    Nashat, Gabrail
    Palomba, M. Lia
    Ansell, Stephen M.
    Eradat, Herbert
    Libby, Edward N., III
    Advani, Ranjana H.
    Hajdenberg, Julio
    Heffner, Leonard T.
    Hoffman, James
    Vesole, David H.
    Simov, Lindsey
    Wyant, Nancy
    Brevard, Julie
    O'Leary, James
    Agrawal, Sudhir
    BLOOD, 2015, 126 (23)
  • [30] Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
    Atkins, Michael B.
    Gravis, Gwenaelle
    Drosik, Kazimierz
    Demkow, Tomasz
    Tomczak, Piotr
    Wong, Shirley S.
    Michaelson, M. Dror
    Choueiri, Toni K.
    Wu, Benjamin
    Navale, Lynn
    Warner, Douglas
    Ravaud, Alain
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3431 - +
12345